India Near Decision To Return Pioglitazone To Market With Boxed Warning
This article was originally published in PharmAsia News
Executive Summary
India regulators plan to lift their suspension of pioglitazone, allowing Abbott Laboratories, Lupin and Sun Pharmaceuticals to return the diabetes drug to the market with a boxed label warning of possible side effects, according to sources.